Bicara Therapeutics BCAX Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's common stock par value per share?
- Bicara Therapeutics (BCAX) reported common stock par value per share of $0.00 in Q1 2026.
- How has Bicara Therapeutics's common stock par value per share changed year-over-year?
- Bicara Therapeutics's common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
- What is the long-term trend for Bicara Therapeutics's common stock par value per share?
- Over 2 years (2023 to 2025), Bicara Therapeutics's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.